Schedule of Summarizes Information About Stock Options (Details) - USD ($) $ / shares in Units, $ in Thousands		12 Months Ended
		Dec. 31, 2022		Dec. 31, 2021
2014 Equity Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Stock Options Outstanding, Beginning Balance		8,720,198		6,798,529
Weighted Average Exercise Price, Beginning Balance		$ 3.39		$ 2.55
Remaining Contractual Term (Years)		6 years 9 months 18 days		7 years 3 months 18 days
Intrinsic Value Outstanding, Beginning Balance	[1]	$ 3,516		$ 2,558
Number of Stock Options, Granted	[2]	4,804,350		2,900,000
Weighted Average Exercise Price, Granted	[2]	$ 1.53		$ 4.90
Number of Stock Option, Exercised		(299,999)		(621,164)
Weighted Average Exercise Price, Exercised		$ 1.01		$ 1.58
Number of Stock Option, Forfeited		(1,655,894)		(357,167)
Weighted Average Exercise Price, Forfeited		$ 3.14		$ 2.82
Number of Stock Options Outstanding, Ending Balance		11,568,655	[3]	8,720,198
Weighted Average Exercise Price, Ending Balance		$ 2.71	[3]	$ 3.39
Remaining Contractual Term (Years)		7 years 4 months 24 days	[3]	6 years 9 months 18 days
Intrinsic Value Outstanding, Ending Balance	[1]		[3]	$ 3,516
Number of Stock Options Vested and exercisable stock options		7,233,965		6,228,106
Weighted Average Exercise Price, Vested and exercisable stock options		$ 2.97		$ 2.88
Remaining Contractual Term (Years), Vested and exercisable stock options		6 years 6 months		5 years 8 months 12 days
Intrinsic Value Exercisable, Ending Balance	[1]			$ 3,245
2018 Equity Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Stock Options Outstanding, Beginning Balance		1,419,242		1,399,242
Weighted Average Exercise Price, Beginning Balance		$ 0.73		$ 0.61
Remaining Contractual Term (Years)		7 years		8 years
Intrinsic Value Outstanding, Beginning Balance	[4]	$ 6,665
Number of Stock Options, Granted	[5]	2,365,000		20,000
Weighted Average Exercise Price, Granted	[5]	$ 3.68		$ 9.08
Number of Stock Option, Exercised		(965,341)
Weighted Average Exercise Price, Exercised		$ 0.72
Number of Stock Option, Forfeited		(253,524)
Weighted Average Exercise Price, Forfeited		$ 3.83
Number of Stock Options Outstanding, Ending Balance		2,565,377	[6]	1,419,242
Weighted Average Exercise Price, Ending Balance		$ 3.14	[6]	$ 0.73
Remaining Contractual Term (Years)		8 years 3 months 18 days	[6]	7 years
Intrinsic Value Outstanding, Ending Balance	[4]	$ 428	[6]	$ 6,665
Number of Stock Options Vested and exercisable stock options		1,119,006		1,337,417
Weighted Average Exercise Price, Vested and exercisable stock options		$ 2.53		$ 0.61
Remaining Contractual Term (Years), Vested and exercisable stock options		7 years 1 month 6 days		7 years
Intrinsic Value Exercisable, Ending Balance	[4]	$ 428		$ 6,370

[1] The intrinsic value is computed as the difference between the quoted price of the PAVmed Inc. common stock on each of December 31, 2022 and December 31, 2021 and the exercise price of the underlying PAVmed Inc. stock options, to the extent such quoted price is greater than the exercise price.

[2] Stock options granted under the PAVmed Inc. 2014 Equity Plan and those granted outside such plan generally vest ratably over twelve quarters, with the vesting commencing with the grant date quarter-end, and have a ten-year contractual term from date-of-grant.

[3] The outstanding stock options presented in the table above, are inclusive of 500,854 stock options granted outside the PAVmed Inc. 2014 Equity Plan, as of December 31, 2022 and December 31, 2021.

[4] The intrinsic value is computed as the difference between the quoted price of the Lucid Diagnostics Inc. common stock on each of December 31, 2022 and December 31, 2021 and the exercise price of the underlying Lucid Diagnostics Inc. stock options, to the extent such quoted price is greater than the exercise price.

[5] Stock options granted under the Lucid Diagnostics Inc. 2018 Equity Plan and those granted outside such plan generally vest ratably over twelve quarters, with the vesting commencing with the grant date quarter-end, and have a ten-year contractual term from date-of-grant.

[6] The outstanding stock options presented in the table above, are inclusive of 423,300 stock options granted outside the Lucid Diagnostics Inc. 2018 Equity Plan, as of December 31, 2022 and December 31, 2021.